Elicio Therapeutics Inc. Common Stock (ELTX)

FairStock Score: 41/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Elicio as a Graham-style analyst, not a scientist. It is a clinical-stage immunotherapy company with no revenue reported in the filed figures and no profit in any of the last four years. In fiscal 2025, the year ended 2025-12-31, it lost $39.6 million, or $2.58 per diluted share; in fiscal 2024, the year ended 2024-12-31, the loss was $51.9 million, or $4.25 per share. More recently, in fiscal Q2 2026, the quarter ended 2026-06-30, it lost $8.2 million, or $0.43 per diluted share. That loss is smaller than the fiscal Q2 2025 loss of $10.6 million, or $0.66 per share, so the burn has moderated, but it is still a cash-consuming enterprise. Trailing free cash flow is negative $37.7 million, an FCF yield of -81.1% against a $46.5 million market cap; the company is spending far more than its market value each year. Balance-sheet and return metrics are ugly: debt-to-equity 1.78, ROE -774.56%, ROCE -77.88%, Altman Z-score -9.52, and Piotroski 2/9. At the $1.77 close on 2026-10-13, FairStock calculations show P/B 4.92 and a negative P/E of -0.82, so this is not a Graham bargain on assets or earnings. The value rests entirely on ELI-002, in Phase II for seven KRAS mutations, and ELI-007. I see no durable moat or earnings power today; the case is binary clinical trial risk, financing risk, and dilution. FairStock Score 41/100 and the Lynch rules find no category because of four straight loss years. This is speculation in science, not a proven business.

In plain English: Elicio Therapeutics is a small experimental cancer vaccine company with no revenue and losses every year. The business looks weak today because it burns cash and depends on clinical trial results, and at $1.77 the price reflects hope for future success rather than current profits. Based on its numbers, it does not look cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer